Clinical Laboratory Improvement Advisory Committee, Centers for Disease Control and Prevention: Notice of Charter Renewal, 12695 [2014-04935]
Download as PDF
<![CDATA[
12695
Federal Register / Vol. 79, No. 44 / Thursday, March 6, 2014 / Notices
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS
Information collection (see above list ‘‘Burden
statement’’ for legend)
Number of
Respondents
Number of
responses per
respondent
Average
burden per
response
(hours)
Total burden
hours
(a) .....................................................................................................................
(b) .....................................................................................................................
(c) .....................................................................................................................
(d) .....................................................................................................................
(e) .....................................................................................................................
(f) ......................................................................................................................
(g) .....................................................................................................................
(h) .....................................................................................................................
(i) ......................................................................................................................
63
63
63
63
63
63
63
63
63
1
1
3
3
1
1
3
3
3
8
12
12
14
10
8
8
3
8
504
756
2268
2646
630
504
1512
567
1512
Total ..........................................................................................................
63
19
83
10,899
Darius Taylor,
Deputy, Information Collection Clearance
Officer.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2014–04931 Filed 3–5–14; 8:45 am]
Food and Drug Administration
BILLING CODE 4150–24–P
[Docket No. FDA–2014–N–0237]
Report to Congress; Report on the
Food and Drug Administration’s Policy
To Be Proposed Regarding Premarket
Notification Requirements for
Modifications to Legally Marketed
Devices; Notice to Public of Web Site
Location of Report to Congress
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
tkelley on DSK3SPTVN1PROD with NOTICES6
Clinical Laboratory Improvement
Advisory Committee, Centers for
Disease Control and Prevention:
Notice of Charter Renewal
AGENCY:
ACTION:
This gives notice under the Federal
Advisory Committee Act (Public Law
92–463) of October 6, 1972, that the
Clinical Laboratory Improvement
Advisory Committee, Centers for
Disease Control and Prevention (CDC),
Department of Health and Human
Services (HHS), has been renewed for a
2-year period through February 19,
2016.
For information, contact Devery
Howerton, Ph.D., Designated Federal
Officer, Clinical Laboratory
Improvement Advisory Committee,
1600 Clifton Road NE., Mailstop E–56,
Atlanta, Georgia 30333, telephone 404–
498–2602 or via email at dxh7@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2014–04935 Filed 3–5–14; 8:45 am]
BILLING CODE 4163–18–P
VerDate Mar<15>2010
17:07 Mar 05, 2014
Jkt 232001
Food and Drug Administration,
HHS.
Notice.
The Food and Drug
Administration (FDA or the Agency) is
announcing the Web site location where
the Agency has posted the report
entitled ‘‘Report to Congress; Report on
FDA’s Policy to be Proposed Regarding
Premarket Notification Requirements for
Modifications to Legally Marketed
Devices.’’ In addition, FDA has
established a docket where stakeholders
may provide comments.
DATES: Submit either electronic or
written comments by June 4, 2014.
ADDRESSES: Submit electronic
comments on this document to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Mike Ryan, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 1615, Silver Spring,
MD 20993–0002, 301–796–6283.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Background
The Food and Drug Administration
Safety and Innovation Act (FDASIA)
(Pub. L. 112–144) became law on July 9,
PO 00000
Frm 00010
Fmt 4703
Sfmt 4703
2012. FDASIA added section 510(n)(2)
to the Federal Food, Drug, and Cosmetic
Act (the FD&C Act) (21 U.S.C.
360(n)(2)). This new provision requires,
no later than 18 months after enactment
of FDASIA, the Secretary of Health and
Human Services to submit to the
Committee on Energy and Commerce of
the House of Representatives and the
Committee on Health, Education, Labor,
and Pensions of the Senate a report on
when a premarket notification under
section 510(k) of the FD&C Act (or a
‘‘510(k)’’) should be submitted for a
modification to a legally marketed
510(k) device. This report fulfills that
requirement.
This notice announces the Web site
location of ‘‘Report to Congress; Report
on FDA’s Policy to be Proposed
Regarding Premarket Notification
Requirements for Modifications to
Legally Marketed Devices.’’ FDA invites
interested persons to submit comments
on this report. FDA has established a
docket where comments may be
submitted (see ADDRESSES). FDA
believes this docket is an important tool
for receiving information from
interested parties and for sharing this
information with the public. To access
‘‘Report to Congress; Report on FDA’s
Policy to be Proposed Regarding
Premarket Notification Requirements for
Modifications to Legally Marketed
Devices,’’ visit FDA’s Web site https://
www.fda.gov/AboutFDA/CentersOffices/
OfficeofMedicalProductsandTobacco/
CDRH/CDRHReports/ucm269873.htm.
II. Request for Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
E:\FR\FM\06MRN1.SGM
06MRN1
]]>Agencies
[Federal Register Volume 79, Number 44 (Thursday, March 6, 2014)]
[Notices]
[Page 12695]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-04935]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Clinical Laboratory Improvement Advisory Committee, Centers for
Disease Control and Prevention: Notice of Charter Renewal
This gives notice under the Federal Advisory Committee Act (Public
Law 92-463) of October 6, 1972, that the Clinical Laboratory
Improvement Advisory Committee, Centers for Disease Control and
Prevention (CDC), Department of Health and Human Services (HHS), has
been renewed for a 2-year period through February 19, 2016.
For information, contact Devery Howerton, Ph.D., Designated Federal
Officer, Clinical Laboratory Improvement Advisory Committee, 1600
Clifton Road NE., Mailstop E-56, Atlanta, Georgia 30333, telephone 404-
498-2602 or via email at dxh7@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2014-04935 Filed 3-5-14; 8:45 am]
BILLING CODE 4163-18-P
